Cd28 pathway immunoregulation

Details Cd28 pathway immunoregulation Cd28 pathway immunoregulation

A - Human Necessities

61

K

A61K 39/395 (2006.01) A61K 31/395 (2006.01) A61K 35/14 (2006.01) A61K 35/18 (2006.01) A61K 35/28 (2006.01) A61K 38/04 (2006.01) A61K 38/17 (2006.01) A61K 38/46 (2006.01) A61K 39/39 (2006.01) C07K 14/705 (2006.01) C07K 16/00 (2006.01) C07K 16/28 (2006.01) A61K 38/00 (2006.01) C12N 5/06 (2006.01)

Patent

CA 2133075

2133075 9319767 PCTABS00027 Immunotherapy of the present invention involves the regulation of the T cell immune response through the activation or suppression/inactivation of the CD28 pathway. Induction of activated T cell lymphokine production occurs upon stimulatory binding of the CD28 surface receptor molecule, even in the presence of conventional immunosuppressants. Inhibition of CD28 receptor binding to an appropriate stimulatory ligand or inactivation of the CD28 signal transduction pathway through other means down-regulates CD28-pathway related T cell lymphokine production and its resulting effects.

Affiliated with

Also associated with

Rating

Cd28 pathway immunoregulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cd28 pathway immunoregulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cd28 pathway immunoregulation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1466232